Identification of Novel Features to Assess Risk and Improve Therapeutic Decision Making for Prostate Cancer Through a Novel High-Parameter Imaging System
Abstract
About 15 of men will be diagnosed with prostate cancer and many will face difficult treatment decisions. This projects goal is to develop and apply a novel imaging strategy that increases the information and potential clinical utility from prostate biopsy samples. Combining two high-dimensional imaging methods: antibody-based imaging mass cytometry (IMC), and mass spectroscopy imaging (MSI) that are layered together, the goal is to generate exceptionally detailed maps of the cells, molecules, and structures from tumor samples. These layered multi-modal images can be used to identify markers that improve assessments of risk and may ultimately inform clinical decisions. In the first year of the project, despite challenges resulting from the COVID19 pandemic, we are nearing completion of method development and optimization studies, generated a tissue microarray containing (TMA) more than 80 prostate cancer biopsy samples, and have nearly completed imaging of the xTMA by MSI. Work on applying the IMC platform to the TMA is ongoing. However, using data generated to date, significant progress was made in developing a novel computational workflow to integrate and analyze high-parameter imaging data. The technical information, methods, and protocols generated will be of value to completing the aims of this study, as well as to the larger scientific community. Similarly, the completed analysis framework will address a previously unsolved challenge and advance the application of cutting-edge imaging methods to identify biological correlates. These methods and resulting insights aim to ultimately improve outcomes for cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2021
- Accession Number
- AD1147312
Entities
People
- Patrick M. Reeves
Organizations
- Massachusetts General Hospital